Adjuvants that activated DCs and might trigger protective antitumor T-cell responses were conveyed by RT-TEX together with tumor antigens.When the STING signaling pathway is used for anti-tumor therapy, therapeutic window and toxic side effects should be considered, and excessive activation of the pathway is associated with the occurrence of related injuries. Here, STING1 is linked to neoplasm.